Sidoti Events, LLC's Virtual May Micro-Cap Conference

Sidoti Events, LLC's Virtual May Micro-Cap Conference

Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day May Micro-Cap Conference taking place Wednesday and Thursday, May 8-9, 2024. The presentation schedule is subject to change. Please visit www.sidoti.comevents for the most updated version and webinar links

Presentation Schedule

*All Times EST

Wednesday, May 8, 2024 (Day 1)

8:30-9:00

Perfect Corp (PERF)

*****

Evaxion (EVAX)

9:15-9:45

CPS Technologies Corp. (CPSH)

*****

Talisker Resources Ltd. (TSKFF)

10:00-10:30

Genius Group (GNS)

L.B. Foster (FSTR)

Alico Inc. (ALCO)

10:45-11:15

AstroNova, Inc. (ALOT)

*****

Athira Pharma (ATHA)

11:30-12:00

*****

Apogee Enterprises, Inc. (APOG)

MDU Resources Group, Inc. (MDU)

12:15-12:45

ZYUS Life Sciences Inc. (ZYUS)

Forum Energy Technologies (FET)

Flexsteel Industries, Inc. (FLXS)

1:00-1:30

NCS Multistage (NCSM)

Innovative Solutions & Support (ISSC)

LifeVantage Corporation (LFVN)

1:45-2:15

American Public Education (APEI)

*****

Cherry Hill Mortgage Investment Corp. (CHMI)

2:30-3:00

*****

Volato Group, Inc. (SOAR)

Lee Enterprises Inc (LEE)

3:15-3:45

*****

Solaris Oilfield Infrastructure (SOI)

Genprex, Inc. (GNPX)

4:00-4:30

AppTech Payments Corp. (APCX)

*****

HF Foods Group Inc. (HFFG)

1x1s Only

(8th)

Bassett Furniture (BSET)

Civeo Corporation (CVEO)

Manitex International (MNTX)

*All Times EST

Thursday, May 9, 2024 (Day 2)

9:15-9:45

ZOOZ Power Ltd. (ZOOZ)

FendX Technologies (FDXTF)

*****

10:00-10:30

Anterix (ATEX)

*****

Mistras Group (MG)

10:45-11:15

LeddarTech Holdings, Inc. (LDTC)

*****

Regional Management (RM)

11:30-12:00

Synchronoss Technologies (SNCR)

Wealth Minerals LTD (WML)

Anixa Biosciences, Inc. (ANIX)

12:15-12:45

Union Jack Oil plc (UJO)

Global Crossing Airlines Group (JET)

Spectral AI (MDAI)

1:00-1:30

Owlet, Inc. (OWLT)

Vince Holding Corp. (VNCE)

*****

1:45-2:15

Sato Technologies Corp (SATO)

*****

FitLife Brands, Inc. (FTLF)

2:30-3:00

Calidi Biotherapeutics, Inc. (CLDI)

*****

TruGolf Holdings, Inc. (TRUG)

1x1s Only

(9th)

Beazer Homes (BZH)

Gulf Island Fabrication (GIFI)

*****

About Sidoti Events, LLC ("Events") and Sidoti & Company, LLC ("Sidoti")
In 2023, Sidoti & Company, LLC (www.sidoti.com) formed an affiliate company, Sidoti Events, LLC in order to focus exclusively on its rapidly growing conference business and to more directly serve the needs of presenters and attendees. The relationship allows Events to draw on the 25 years of experience Sidoti has as a premier provider of independent securities research focused specifically on small and microcap companies and the institutions that invest in their securities, with most of its coverage in the $200 million-$5 billion market cap range. Sidoti's coverage universe comprises approximately 150 equities of which greater than 50 percent participate in the firm's rapidly growing Company Sponsored Research ("CSR") program. In 2024, Sidoti established Lighthouse Equity Research as an extension of its CSR program to meet the specific needs of companies not valued using traditional metrics or that face challenges obtaining coverage due to political risks or other factors. Events is a leading provider of corporate access through the eight investor conferences it hosts each year. By virtue of its direct ties to Sidoti, Event's benefits from Sidoti's small- and microcap-focused nationwide sales force, which has connections with 2,500 institutional relationships in North America. This enables Events to provide multiple forums for meaningful interaction for small and microcap issuers and investors specifically interested in companies in the sector.

SOURCE: Sidoti Events, LLC



View the original press release on accesswire.com

News Provided by ACCESSWIRE via QuoteMedia

ATHA
The Conversation (0)
Athira Pharma Inc.

Athira Pharma Inc.

Athira Pharma Inc is a biotechnology company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The company is developing treatments for Alzheimer's disease and Parkinson's disease.

Standard Uranium Confirms Strong Radioactivity During Successful Exploration Program at the Corvo Uranium Project

Standard Uranium Confirms Strong Radioactivity During Successful Exploration Program at the Corvo Uranium Project

Standard Uranium Ltd. (TSXV: STND,OTC:STTDF) (OTCQB: STTDF) (FSE: 9SU0) ("Standard Uranium" or the "Company") is pleased to announce preliminary results from its 2025 exploration programs the Corvo Uranium Project ("Corvo", or the "Project"), currently under a three-year earn-in option agreement with Aventis Energy Inc. (CSE: AVE) ("Aventis") . From July 4 to July 16, 2025, the Company completed a detailed mapping and sampling program across historical uranium showings and zones of interest on the Project.

Highlights:

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Stallion Uranium Appoints Peter Dembicki to Board of Directors, Initiates Haystack Intelligent Targeting Study

Stallion Uranium Appoints Peter Dembicki to Board of Directors, Initiates Haystack Intelligent Targeting Study

Stallion Uranium Corp. (the " Company " or " Stallion ") ( TSX-V: STUD ; OTCQB: STLNF ; FSE: B76 ) is pleased to announce the appointment of Mr. Peter Dembicki to its Board of Directors, bringing significant capital markets and governance expertise to the Company. In tandem with this strategic addition, Stallion has also initiated the Haystack Intelligent Targeting Study leveraging cutting-edge AI technology to refine drill targeting across its large-scale uranium exploration portfolio in the Athabasca Basin.

Peter Dembicki; Strengthening Corporate Oversight and Market Expertise:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Stallion Uranium Announces Grant of Options

Stallion Uranium Announces Grant of Options

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

Stallion Uranium Corp. (the " Company " or " Stallion " ) ( TSX-V: STUD ; OTCQB: STLNF ; FSE: FE0 ) is pleased to announce that under the Company's stock option plan dated October 8, 2024 (the " Plan "), the Company has granted a total of 3,100,000 stock options (" Options ") to certain directors, officers and consultants of the Company.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Stallion Uranium Completes Second and Final Tranche of Oversubscribed $15,000,000 Non-Brokered Private Placement

Stallion Uranium Completes Second and Final Tranche of Oversubscribed $15,000,000 Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

Stallion Uranium Corp. (the " Company " or " Stallion " ) ( TSX-V: STUD ; OTCQB: STLNF ; FSE: FE0 ) is pleased to announce that it has closed a second and final tranche of its previously announced non-brokered private placement of units and flow-through units (the " Offering "). This closing consisted of 22,305,600 units of the Company (each a " NFT Unit ") at a price of $0.20 per NFT Unit for aggregate gross proceeds of $4,461,120 and 30,139,600 flow-through units (each a " FT Unit ") at a price of $0.20 per FT Unit for aggregate gross proceeds of $6,027,920.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Stallion Uranium Completes First Tranche of Non-Brokered Private Placement and Announces Upsizing

Stallion Uranium Completes First Tranche of Non-Brokered Private Placement and Announces Upsizing

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

Stallion Uranium Corp. (the " Company " or " Stallion ") ( TSX-V: STUD ; OTCQB: STLNF ; FSE: FE0 ) is pleased to announce that it has closed a first tranche of its previously announced non-brokered private placement of units and flow-through units (the " Offering "). This closing consisted of 21,239,800 units of the Company (each a " NFT Unit ") at a price of $0.20 per NFT Unit for aggregate gross proceeds of $4,247,960 and 1,315,000 flow-through units (each a " FT Unit ") at a price of $0.20 per FT Unit for aggregate gross proceeds of $263,000.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Imagion Biosystems

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, is pleased to provide shareholders with a progress update regarding the Company’s business and MagSense® HER2 Breast Cancer diagnostic imaging program, supporting the planned Phase 2 Clinical Trial expected to commence towards the end of 2025.

Keep reading...Show less
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare.

But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no indication that US hospitals are stockpiling equipment ahead of expected price hikes, according to recent findings from GlobalData.

Keep reading...Show less
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This establishes the timeline for the planned safety and efficacy futility interim analysis by an independent Data Monitoring Committee (DMC).

Keep reading...Show less
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access Emyria’s Empax PTSD care program delivered in association with Perth Clinic.

Keep reading...Show less
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will integrate HITIQ’s PROTEQT technology. The result is a fully developed, market-ready solution that merges HITIQ’s smart sensor technology with Shock Doctor’s unmatched global production partner capabilities.

Keep reading...Show less
HeartSciences Inc

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems

Keep reading...Show less

Latest Press Releases

Related News